491.47

5.69% 26.45

Vertex Pharmaceuticals Inc (VRTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt VRTX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$465.02

Offen:

$471.645

24-Stunden-Volumen:

2.92M

Relative Volume:

2.02

Marktkapitalisierung:

$124.70B

Einnahmen:

$11.74B

Nettoeinkommen (Verlust:

$3.68B

KGV:

34.64

EPS:

14.1888

Netto-Cashflow:

$3.34B

1W Leistung:

+2.84%

1M Leistung:

+8.09%

6M Leistung:

+24.13%

1J Leistung:

+6.25%

1-Tages-Spanne:

$471.64

$503.88

1-Wochen-Bereich:

$454.40

$503.88

52-Wochen-Spanne:

$362.50

$519.68

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Firmenname

Vertex Pharmaceuticals Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (622)

Telefon

(617) 341-6393

Adresse

50 NORTHERN AVENUE, BOSTON, MA

Mitarbeiter

6,100

Twitter

@VertexPharma

Nächster Verdiensttermin

2026-02-12

Neueste SEC-Einreichungen

VRTX's Discussions on Twitter

Compare VRTX vs REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Fortgesetzt	Barclays	Overweight
2026-01-22	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2026-01-12	Hochstufung	Bernstein	Mkt Perform → Outperform
2026-01-07	Fortgesetzt	UBS	Buy
2026-01-06	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-12-03	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-11-13	Eingeleitet	Scotiabank	Sector Outperform
2025-09-25	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-09-03	Eingeleitet	Raymond James	Mkt Perform
2025-08-06	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-05-07	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-05-06	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-02-12	Hochstufung	Canaccord Genuity	Sell → Hold
2025-02-11	Hochstufung	Canaccord Genuity	Sell → Hold
2025-01-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2024-12-20	Bestätigt	H.C. Wainwright	Buy
2024-12-19	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-09	Hochstufung	Jefferies	Hold → Buy
2024-11-14	Eingeleitet	Citigroup	Buy
2024-10-16	Eingeleitet	Scotiabank	Sector Perform
2024-10-10	Fortgesetzt	Raymond James	Mkt Perform
2024-08-05	Herabstufung	Barclays	Overweight → Equal Weight
2024-06-27	Eingeleitet	Redburn Atlantic	Buy
2024-04-11	Hochstufung	Evercore ISI	In-line → Outperform
2024-02-15	Eingeleitet	Wolfe Research	Outperform
2024-02-06	Herabstufung	Evercore ISI	Outperform → In-line
2024-02-02	Herabstufung	Bernstein	Outperform → Mkt Perform
2024-01-31	Herabstufung	Maxim Group	Buy → Hold
2024-01-31	Herabstufung	Robert W. Baird	Neutral → Underperform
2024-01-24	Herabstufung	Canaccord Genuity	Hold → Sell
2023-12-14	Bestätigt	RBC Capital Mkts	Sector Perform
2023-05-30	Eingeleitet	William Blair	Outperform
2023-05-04	Fortgesetzt	Piper Sandler	Overweight
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-01-18	Eingeleitet	Canaccord Genuity	Hold
2023-01-17	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-12-19	Herabstufung	Jefferies	Buy → Hold
2022-07-13	Eingeleitet	Cantor Fitzgerald	Overweight
2022-06-01	Hochstufung	Maxim Group	Hold → Buy
2022-05-23	Eingeleitet	SVB Leerink	Mkt Perform
2022-05-06	Herabstufung	Robert W. Baird	Outperform → Neutral
2022-05-03	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-02-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2022-01-27	Bestätigt	JP Morgan	Overweight
2022-01-27	Bestätigt	Morgan Stanley	Underweight
2022-01-27	Bestätigt	RBC Capital Mkts	Outperform
2022-01-27	Bestätigt	Stifel	Hold
2022-01-27	Bestätigt	Wolfe Research	Outperform
2022-01-20	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-12-09	Eingeleitet	Wells Fargo	Overweight
2021-11-19	Eingeleitet	BMO Capital Markets	Market Perform
2021-11-19	Herabstufung	Piper Sandler	Overweight → Neutral
2021-09-09	Herabstufung	Stifel	Buy → Hold
2021-09-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-07-20	Herabstufung	SVB Leerink	Mkt Perform → Underperform
2021-07-19	Fortgesetzt	Wolfe Research	Outperform
2021-07-01	Eingeleitet	Raymond James	Mkt Perform
2021-06-11	Herabstufung	Daiwa Securities	Outperform → Neutral
2021-02-23	Hochstufung	Robert W. Baird	Neutral → Outperform
2021-02-02	Bestätigt	H.C. Wainwright	Buy
2020-12-30	Eingeleitet	Daiwa Securities	Outperform
2020-11-30	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2020-11-20	Eingeleitet	Bernstein	Outperform
2020-10-28	Eingeleitet	UBS	Buy
2020-07-31	Bestätigt	H.C. Wainwright	Buy
2020-07-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-04-30	Bestätigt	H.C. Wainwright	Buy
2020-04-28	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-31	Herabstufung	Robert W. Baird	Outperform → Neutral
2019-11-19	Hochstufung	Guggenheim	Neutral → Buy
2019-11-12	Eingeleitet	SunTrust	Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Buy
2019-09-03	Hochstufung	Goldman	Neutral → Buy
2019-08-01	Herabstufung	Needham	Buy → Hold
2019-05-23	Fortgesetzt	Citigroup	Buy
2019-05-21	Eingeleitet	Credit Suisse	Outperform
2019-04-12	Eingeleitet	Evercore ISI	In-line
2019-03-26	Hochstufung	William Blair	Mkt Perform → Outperform
2019-03-19	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2019-02-06	Herabstufung	Maxim Group	Buy → Hold

Alle ansehen

Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten

03:28 AM

Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

03:28 AM

12:06 PM

The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 - The Motley Fool

Feb 13, 2026

Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq

Feb 13, 2026

VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase - Finviz

Feb 13, 2026

Vertex Pharmaceuticals (VRTX): Scotiabank Raises Price Target to $558 | VRTX Stock News - GuruFocus

Feb 13, 2026

RBC Capital Lowers Vertex Pharmaceuticals' (VRTX) Price Target | - GuruFocus

Feb 13, 2026

VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz

Feb 13, 2026

Vertex Pharmaceuticals (VRTX) Analyst Maintains Rating and Raises Price Target | VRTX Stock News - GuruFocus

Feb 13, 2026

Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says - marketscreener.com

Feb 13, 2026

Top Biotech Stocks To ConsiderFebruary 13th - MarketBeat

Feb 13, 2026

Busy with Casgevy and Journavx launches, Vertex sets ambitious $500M revenue goal for non-CF meds this year - Fierce Pharma

Feb 13, 2026

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Topline Grows 10% - FXDailyReport.Com

Feb 13, 2026

Vertex Prepares Povetacicept For APRIL/BAFF Battle - Citeline News & Insights

Feb 13, 2026

Agree To Purchase Vertex Pharmaceuticals At $320, Earn 4.4% Using Options - Nasdaq

Feb 13, 2026

Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp - BioSpace

Feb 13, 2026

CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz

Feb 13, 2026

Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News - GuruFocus

Feb 13, 2026

Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays - Insider Monkey

Feb 13, 2026

AI for investors - MLQ.ai

Feb 13, 2026

Vertex Pharmaceuticals Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 13, 2026

Bernstein Adjusts Vertex Pharmaceuticals Price Target to $577 From $572, Maintains Outperform Rating - marketscreener.com

Feb 13, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to "Outperform" at Oppenheimer - MarketBeat

Feb 13, 2026

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026

Vertex Pharma Q4 2025 Earnings Results - AlphaStreet News

Feb 13, 2026

All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts - BioSpace

Feb 13, 2026

Vertex Pharmaceuticals (VRTX) Receives Boosted Price Target from HC Wainwright & Co. | VRTX Stock News - GuruFocus

Feb 13, 2026

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 11 Analysts - Benzinga

Feb 13, 2026

11,989 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by ING Groep NV - MarketBeat

Feb 13, 2026

Atria Investments Inc Acquires 2,418 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Feb 13, 2026